Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02104388 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Corneal Epithelial Disorders

Interventions

DRUG: SJP-0035 Ophthalmic Solution
DRUG: Vehicle of SJP-0035 Ophthalmic Solution

Sponsor

Senju Pharmaceutical Co., Ltd.